The United States Food and Drug Administration (FDA) has removed the partial hold it had placed on the clinical development of Telik, Inc’s investigative small molecule Telcyta (canfosfamide HCL, TLK286).
Telcyta is a tumor-activated small molecule investigative agent that is under evaluation for the treatment of advanced ovarian and non-small cell lung cancer. Telcyta was developed using the proprietary drug discovery technology referred to as TRAP®, which is a procedure that allows for the rapid and efficient discovery of potential small molecule drug candidates.
The FDA finished a completed review of data including Telcyta, allowing for subsequent resumption of clinical trial development.
© 1998-2007 OncoEd.com All Rights Reserved.
These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers should verify all information and data before administering any drug, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein.
Patient Home
